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 Tumour property (primary prostate cancers) 
1 Primary prostate cancers largely consist of replicating cells with an aberrant luminal 
phenotype (AR+, PSA secreting, changed energy requirements) whereas in normal 
tissues luminal cells rarely divide. 
2 Primary cancers have lost more than 99% of basal cells compared to normal 
prostate, where there is (in man) a contiguous basal layer lining prostatic glands. 
3 Basement membrane, which provides a barrier between the stromal and epithelial 
compartments has all but disappeared in higher grade primary cancers. 
4 The stromal compartment in cancers has a novel more embryonal phenotype (see 
above) termed ‘reactive stroma’. 
5 The intratumoral immune cell components, which include both lymphocytes and 
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repetitions.		For	example, hypermethylated enhancers were highly enriched for TFBSs of 
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Plasticity of tumor cells to their microenvironment 
(Location and presence of selective drug)
Development of further drug-induced and selected mutations
Predictions:
• No pre-existing resistant cells
• Treatment induces or selects for 
resistant cells
• Mature cancer cell trans-






• Resistant Stem-like cells
• Treatment results in 
progressive changes to SC
• Differentiation hierarchy is re-
established (dependent in 
new post-treatment 
microenvironment)
Hierarchical or Stem Cell Model
De-differentiation/plasticity
Residual/pre-existing SC
Adaptation/plasticity to permit growth 

















Pre-existing drug resistant (stem-like) 
cell initiates resistant population
A
Figure 4
Cumulative incidence of and time from study entry (A) 
to symptomatic progression of hormone refractory 
disease after immediate or deferred androgen
deprivation and (B) to objective progression of 
























Depletion of blood (Lin+) 
and endothelial (CD31+) 














Genomic methylation in 
luminal vs basal cells from the 
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